Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug
Demonstrates leadership in AI driven pharma through Accenture partnershipBristol Myers Squibb, one of the world’s largestbiopharmaceutical companies, and Accenture, a global professional services firm, todayannounced the official opening of a new AI-powered content hub, ‘Mosaic’, in Mumbai,India.The first-of-its-kind, end-to-end, generative AI-enabled content hub will accelerateBristol
